Sanjay Ahuja | Blood, Heart, Lung, and ...

Dr. Sanjay Ahuja, MD, MSc, MBA

Claim this profile

University Hospitals Health System Cleveland

Studies Hemophilia
Studies Hemophilia A
5 reported clinical trials
7 drugs studied

Area of expertise

1

Hemophilia

Sanjay Ahuja, MD, MSc, MBA has run 4 trials for Hemophilia. Some of their research focus areas include:

FVIII Level positive
FVIII Gene Mutation positive
2

Hemophilia A

Sanjay Ahuja, MD, MSc, MBA has run 4 trials for Hemophilia A. Some of their research focus areas include:

FVIII Level positive
FVIII Gene Mutation positive

Affiliated Hospitals

Image of trial facility.

University Hospitals Health System Cleveland

Image of trial facility.

UHHS Cleveland

Clinical Trials Sanjay Ahuja, MD, MSc, MBA is currently running

Image of trial facility.

Natural History Study

for Blood Disorders

In parallel with the growth of ATHN's clinical studies, the number of new therapies for all blood disorders is increasing significantly. Some of the recently FDA-approved therapies for congenital and acquired hematologic conditions have not yet demonstrated long-term safety and effectiveness beyond the pivotal trials that led to their approval. In addition, results from well controlled, pivotal studies often cannot be replicated once a therapy has been approved for general use.2,3,4,5 In 2019 alone, the FDA has issued approvals for 24 new therapies for congenital and acquired hematologic conditions.6 In addition, almost 10,000 new studies for hematologic diseases are currently registered on www.clinicaltrials.gov.7 With this increase in potential new therapies possible, it is imperative that clinicians and clinical researchers in the field of non-neoplastic hematology have a uniform, secure, unbiased, and enduring method to collect long-term safety and efficacy data. As emphasized in a recently published review, accurate, uniform and quality national data collection is critical in clinical research, particularly for longitudinal cohort studies covering a lifetime of biologic risk.8

Recruiting

1 award

N/A

1 criteria

Image of trial facility.

SEVENFACT®

for Hemophilia

Phase IV multi-center, US-centric, open-label, safety study enrolling participants with Hemophilia A or B with inhibitors, 12 years of age and older, who are either on long term prophylactic treatment (e.g., emicizumab) at risk of experiencing a breakthrough bleeding event (BE), or who are not on prophylactic treatment who may need to control a BE.

Recruiting

3 awards

Phase 4

6 criteria

More about Sanjay Ahuja, MD, MSc, MBA

Clinical Trial Related

5 years of experience running clinical trials · Led 5 trials as a Principal Investigator · 3 Active Clinical Trials

Treatments Sanjay Ahuja, MD, MSc, MBA has experience with

  • Clotting Factor Replacement Product
  • Coagulation Factor VIIa [recombinant]-jncw
  • ATHN Transcends
  • ITI
  • PEGylated Recombinant Factor VIII
  • Antihemophilic Factor (Recombinant)

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?

What does Sanjay Ahuja, MD, MSc, MBA specialize in?

Is Sanjay Ahuja, MD, MSc, MBA currently recruiting for clinical trials?

Are there any treatments that Sanjay Ahuja, MD, MSc, MBA has studied deeply?

What is the best way to schedule an appointment with Sanjay Ahuja, MD, MSc, MBA?

What is the office address of Sanjay Ahuja, MD, MSc, MBA?

Is there any support for travel costs?